Edition:
United Kingdom

Denali Therapeutics Inc (DNLI.OQ)

DNLI.OQ on NASDAQ Stock Exchange Global Select Market

20.88USD
20 Sep 2018
Change (% chg)

$0.46 (+2.25%)
Prev Close
$20.42
Open
$20.57
Day's High
$21.20
Day's Low
$20.40
Volume
358,429
Avg. Vol
145,030
52-wk High
$25.50
52-wk Low
$12.36

Summary

Name Age Since Current Position

Marc Tessier-Lavignec

58 Chairman of the Board, Co-Founder

Ryan Watts

42 2016 President, Chief Executive Officer, Co-Founder, Director

Alexander Schuth

44 2015 Co-Founder, Chief Operating Officer, Secretary

Steve Krognes

49 2015 Chief Financial Officer, Treasurer

Dana Andersen

2018 Chief Technology Officer and Manufacturing Officer

Carole Ho

45 2015 Chief Medical Officer and Head of Development

Jay Flatley

65 2015 Director

Douglas Cole

57 2015 Independent Director

Peter Klein

55 2018 Independent Director

Robert Nelsen

55 2015 Independent Director

Vicki Sato

69 2015 Independent Director

David Schenkein

60 2015 Independent Director

Biographies

Name Description

Marc Tessier-Lavignec

Dr. Marc Tessier-Lavignec is Chairman of the Board, Co-Founder of Denali Therapeutics Inc. Marc is currently President of Stanford University. Prior to his current role, Marc served as President of The Rockefeller University in New York City, where he was also Carson Family Professor and Head of the Laboratory of Brain Development and Repair. Marc has held faculty positions at the University of California, San Francisco, and Stanford University, before joining Genentech, where he served as Executive Vice President of Research and Chief Scientific Officer, overseeing the company’s disease research and drug discovery efforts. He is the recipient of numerous scientific awards, including being elected a member of the National Academy of Science and the National Academy of Medicine. Marc obtained undergraduate degrees from McGill University and Oxford University, where he was a Rhodes Scholar, and a Ph.D. in neurophysiology from University College London.

Ryan Watts

Mr. Ryan Watts, Ph.D. is President, Chief Executive Officer, Co-Founder, Director of Denali Therapeutics Inc. Ryan previously served as Director of the Department of Neuroscience at Genentech, where he was employed for 11 years. During his tenure there, he led the company’s entry into neuroscience, building a department and advancing multiple programs for neurological disease from discovery to clinical testing. Ryan’s own laboratory focused on drug discovery for Alzheimer’s disease and on understanding mechanisms of neurodegeneration guided by human genetics. Ryan is also a leader in the development of improved methods for delivering therapeutic antibodies across the blood-brain barrier. He obtained his B.S. from the University of Utah and his Ph.D. in biological sciences from Stanford University.

Alexander Schuth

Mr. Alexander Schuth M.D. co-founders and has served as our Chief Operating Officer since March 2015 and as Secretary since June 2015. Dr. Schuth co-founded and joined Denali from Genentech, where he held various roles of increasing responsibility between 2005 and 2015; from September 2014 to March 2015, Dr. Schuth served as Head of Technology Innovation and Diagnostics Partnering; from March 2010 to September 2014, Dr. Schuth served as Head of Neuroscience Partnering; from January 2007 to March 2010, Dr. Schuth worked in the business development team; and from August 2005 to January 2007, Dr. Schuth worked as an R&D finance manager. From January 2001 to May 2003, he served as Investment Banking Associate in the equity capital markets group at Merrill Lynch in London. He currently serves on the board of directors of Molecular Health, a privately held biopharmaceutical company. Dr. Schuth received his M.B.A. from The Wharton School of the University of Pennsylvania and his M.D. from the Charite Medical School at the Humboldt University in Berlin, Germany.

Steve Krognes

Mr. Steve E. Krognes is Chief Financial Officer since October 2015 and Treasurer since November 2015. Mr. Krognes joined Denali from Genentech, where he served as Chief Financial Officer and a member of the Executive Committee from April 2009 to September 2015. Mr. Krognes also oversaw Genentech’s Site Services organization between 2011 and 2015, and Genentech’s IT organization between 2009 and 2011. He chaired the Genentech Access to Care Foundation between 2009 and 2015. From January 2004 to April 2009, Mr. Krognes served as Head of Mergers & Acquisitions and a member of the Finance Executive Committee at Roche, a Swiss biotechnology company. From July 2002 to December 2003, Mr. Krognes served as Director of M&A at Danske Bank based in Norway. From April 2000 to June 2002, he served as a Venture Capitalist with Pylonia Ventures, a Swedish venture investments company. Prior to that, Mr. Krognes worked as a consultant at McKinsey and an investment banker at Goldman Sachs, based in London and Boston. Mr. Krognes currently serves as a member of the boards of directors of Corvus Pharmaceuticals, a biopharmaceutical company, RLS Global, a Swedish life science company, and the California Academy of Sciences, a private scientific and educational institution. Mr. Krognes served as a board member of the California Life Science Association between 2010 and 2015. He received his M.B.A. from Harvard Business School and his B.S. in Economics from The Wharton School of the University of Pennsylvania.

Dana Andersen

Dr. Dana Andersen is Chief Technical and Manufacturing Officer of the Company. Dr. Andersen joins Denali from Genentech, where he served in various roles for nearly 23 years, working most recently as Vice President and Global Head of Technical Development Project & Portfolio Management. Prior to this role, he was Vice President of Pharmaceutical Development and held numerous leadership roles spanning biologics manufacturing process development at Genentech. Dr. Andersen is a fellow of the American Institute for Medical and Biological Engineering and received a B.S. from the University of Colorado at Boulder, and a M.S. and Ph.D. from Stanford University, all in chemical engineering with a focus on biological systems.

Carole Ho

Dr. Carole Ho is Chief Medical Officer of the Company. She serves as Head of Development. Carole most recently served as Vice President of Genentech Early Clinical Development. In that role, she was responsible for delivery of pivotal trial-ready drug candidates to the Roche / Genentech late-stage development groups in Neurology, Ophthalmology, Immunology, and Infectious Disease. During her 8 year tenure at Genentech, Carole held positions of increasing responsibility across both the early and late stage clinical development groups with development oversight for multiple therapeutic areas and molecules including crenezumab for Alzheimer’s Disease, ocrelizumab for Multiple Sclerosis, Lampalizumab for dry AMD, and the sBLA approval of Rituxan for Wegener’s granulomatosis and microscopic polyangiitis. Carole received her undergraduate degree in Biochemical Sciences from Harvard College and her M.D. from Cornell University. Carole completed her Medical Internship and Neurology residency at Harvard and served as Chief Resident of Neurology at the Massachusetts General Hospital / Brigham and Women’s Hospital. Prior to Genentech, Carole was on Faculty in the Department of Neurology at Stanford University and subsequently a Medical Director at Johnson and Johnson.

Jay Flatley

Mr. Jay T. Flatley is Director of Denali Therapeutics Inc. He has served as Chief Executive Officer and as a director of Illumina since October 1999. He drives the strategic vision for the company and manages its commercial and corporate functions. Until December 2013, he served in the dual role of President and Chief Executive Officer leading the company through a period of tremendous growth. With the company’s initial success in genotyping and subsequent expansion into whole-genome sequencing, diagnostics, and informatics, sales grew from $1.3 million in 2000 to more than $1.42 billion in 2013. Under Flatley’s leadership, the company launched over 50 major products, acquired several new technologies, and entered multiple markets in the research, applied, and clinical arenas. Illumina is now uniquely positioned to unlock the power of the genome, as the leading provider of genetic analysis technologies. Prior to joining Illumina, Flatley was co-founder, President, Chief Executive Officer, and a director of Molecular Dynamics, Inc., a NASDAQ-listed life sciences company focused on genetic discovery and analysis, from 1994 until its sale to Amersham Pharmacia Biotech Inc. in 1998. He served in various other positions of increasing responsibility with Molecular Dynamics from 1987 to 1994. From 1985 to 1987, Flatley was Vice President of Engineering and Vice President of Strategic Planning at Plexus Computers, a UNIX computer company. Flatley also serves as a director of Coherent, Inc., a NASDAQ-listed provider of photonics-based solutions to commercial and scientific research markets. He holds a B.A. in Economics from Claremont McKenna College and a B.S. and M.S. in Industrial Engineering from Stanford University.

Douglas Cole

Mr. Douglas Cole, M.D. is Independent Director of the company. Dr. Cole joined Flagship Pioneering, which conceives, creates, resources and develops first-in-category life sciences companies, in 2001, and is currently a Managing Partner focused on life science investments. Dr. Cole currently serves on the board of directors of Quanterix Corporation, a public company digitalizing bio marker analysis to advance the science of precision health, and serves on the board of directors of a number of private companies. Previously, Dr. Cole served on the boards of directors of a number of public companies including Agios Pharmaceuticals, Receptos, AVEO Pharmaceuticals, Editas Medicine, Tetraphase Pharmaceuticals and Concert Pharmaceuticals. Dr. Cole received his M.D. from the University of Pennsylvania School of Medicine and his B.A. in English from Dartmouth College.

Peter Klein

Mr. Peter S. Klein is Independent Director of the Company. Mr. Klein has 25 years of experience as a senior finance executive. He served as Chief Financial Officer of Microsoft Corporation from November 2009 until May 2013 and spent over 11 years at Microsoft. Most recently, he served as Chief Financial Officer of WME, a global leader in sports and entertainment marketing, from January 2014 until June 2014. Mr. Klein holds a B.A. from Yale University and an M.B.A from University of Washington. He currently serves on the board of directors of two publicly traded companies: Apptio Inc. and F5 Networks, Inc.

Robert Nelsen

Mr. Robert Nelsen is Independent Director of the company. Mr. Nelsen has served as a Co-founder and Managing Director of ARCH Venture Partners, a venture capital firm focused on early-stage technology companies, or its affiliated entities, since 1986. Mr. Nelsen is a director of Sienna Biopharmaceuticals and Syros Pharmaceuticals, along with certain private companies. Previously, Mr. Nelsen served on the boards of directors of Agios Pharmaceuticals, KYTHERA Biopharmaceuticals, Adolor Corporation, Illumina, Fate Therapeutics, deCODE genetics, NeurogesX, Bellerophon Therapeutics, Sage Therapeutics, Juno Therapeutics and Caliper Life Sciences. He also previously served as trustee of Fred Hutchinson Cancer Research Center. Mr. Nelsen received his M.B.A. from the University of Chicago and his B.S. degrees from the University of Puget Sound with majors in Economics and Biology.

Vicki Sato

Dr. Vicki Sato, Ph.D. is Independent director of the company. From September 2006 until July 2017, Dr. Sato served as a professor of management practice at Harvard Business School. From July 2005 until October 2015, she also had an appointment as Professor of the Practice in the Department of Molecular and Cell Biology at Harvard University. From September 2000 to May 2005, Dr. Sato served as the President of Vertex Pharmaceuticals, a pharmaceutical company, with general management responsibility for business and corporate development, commercial operations, legal and finance, in addition to research and development. From 1992 until 2000, she served as the Chief Scientific Officer and Senior Vice President of Research and Development of Vertex Pharmaceuticals. Dr. Sato joined Vertex Pharmaceuticals in 1992, after serving as Vice President of Research at Biogen, a biotechnology company, where she also served as a member of the Scientific Board. Dr. Sato serves on the boards of directors of Bristol Myers Squibb, Syros Pharmaceuticals and BorgWarner. She previously served on the board of directors of PerkinElmer until April 2017. Dr. Sato received her A.M. and Ph.D. degrees from Harvard University and her A.B. in Biology from Radcliffe College

David Schenkein

Dr. David Schenkein, M.D. is Independent Director of the company. Since August 2009, Dr. Schenkein has served as President and Chief Executive Officer of Agios Pharmaceuticals, a pharmaceuticals company. From April 2006 to July 2009, Dr. Schenkein served as a Senior Vice President of Oncology Development at Genentech. Dr. Schenkein currently serves on the boards of directors of Agios Pharmaceuticals and bluebird bio. Previously, Dr. Schenkein served on the board of directors of Foundation Medicine. He also currently serves as an adjunct attending physician in hematology at Tufts Medical Center. Dr. Schenkein received his M.D. from the State University of New York Upstate Medical School and his B.A. in Chemistry from Wesleyan University.

Basic Compensation

Name Fiscal Year Total

Marc Tessier-Lavignec

632,891

Ryan Watts

1,366,860

Alexander Schuth

1,076,940

Steve Krognes

1,166,560

Dana Andersen

--

Carole Ho

1,368,000

Jay Flatley

633,233

Douglas Cole

604,758

Peter Klein

--

Robert Nelsen

604,244

Vicki Sato

634,449

David Schenkein

632,822
As Of  31 Dec 2017